Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.65 USD
Change Today -0.10 / -1.14%
Volume 4.4K
AEMD On Other Exchanges
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

aethlon medical inc (AEMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/24/14 - $36.00
52 Week Low
09/18/14 - $5.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AETHLON MEDICAL INC (AEMD)

Related News

No related news articles were found.

aethlon medical inc (AEMD) Related Businessweek News

No Related Businessweek News Found

aethlon medical inc (AEMD) Details

Aethlon Medical, Inc. operates as a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was formerly known as Bishop Equities Inc and changed its name to Aethlon Medical, Inc. in March 2000. The company was founded in 1991 and is based in San Diego, California.

10 Employees
Last Reported Date: 01/30/15
Founded in 1991

aethlon medical inc (AEMD) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $400.0K
President and Director
Total Annual Compensation: $240.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $183.0K
Chief Science Officer, Senior Vice President ...
Total Annual Compensation: $195.0K
Compensation as of Fiscal Year 2014.

aethlon medical inc (AEMD) Key Developments

Aethlon Medical, Inc. Announces Health Canada Approval of Ebola Treatment Protocol

Aethlon Medical, Inc. disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens. The Health Canada approved protocol is entitled, "The Treatment of Ebola Virus Disease (EVD) in Humans with the Aethlon Hemopurifier Lectin Affinity Plasmapheresis Device". The protocol allows for an investigational study of Hemopurifier therapy to be conducted in up to 3 human subjects. The objective of the study is to standardize and evaluate the use of the Hemopurifier as supportive care in the treatment of EVD. There is no assurance that the investigational study will result in the collection of clinical data that would support Health Canada licensing requirements. Aethlon further disclosed that the Ebola study protocol had also been approved by the University Health Network (UHN) Research Ethics Board, based in Toronto, Ontario. Previously, Aethlon disclosed that the United States (U.S.) Food and Drug Administration (FDA) approved a clinical protocol to treat Ebola-infected individuals with Hemopurifier therapy in the U.S. The Company has also submitted a Humanitarian Use Device (HUD) application with FDA to support potential market clearance of the Hemopurifier as a treatment for EVD. The first administration of Hemopurifier therapy to an ebola-infected individual occurred at Frankfurt University Hospital in Germany. On November 14, 2014, the resulting Hemopurifier treatment data was presented at the American Society of Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital. Dr. Geiger reported that 242 million Ebola viruses were captured within the Hemopurifier during treatment, a number verified by a post-treatment elution protocol. The elution protocol has since be repeated, which resulted in second measurement of 253 million copies of Ebola virus captured within the Hemopurifier.

Aethlon Medical Inc. Announces Institutional Review Board Approval of Multi-Indication Cancer Study

Aethlon Medical Inc. announced that the Institutional Review Board of the University of California Irvine has approved a multi-indication clinical study entitled 'Plasma Exosome Concentration in Cancer Patients Undergoing Treatment.' Aethlon previously disclosed that it had entered into investigator-initiated clinical trial agreement with UCI which was pending IRB approval. Under the approved clinical protocol the study will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; Breast adenocarcinoma Colorectal Gastric amp; Gastroesophageal Pancreatic Cholangiocarcinoma Lung Head amp; Neck Melanoma and Ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson M.D. The study endpoints include establishing baseline exosome levels and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal changes in circulating exosome concentrations with response to treatment. Recruitment of participants in the study will be through the use of internal and outside referrals to the University of California Irvine Medical Center. The clinical study will also provide data to help direct future clinical investigations of the Aethlon Hemopurifier as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis. The Hemopurifier is a first-in-class biofiltration device that targets the single-use removal of viruses and tumor-derived exosomes from the circulatory system. About Aethlon Medical Inc. Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.

Aethlon Medical, Inc. will Change its Ticker to AEMD from AEMDD

Effective May 11, 2015, Aethlon Medical, Inc. will change its Pink Sheets LLC stock ticker symbol to AEMD from AEMDD.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMD:US $8.65 USD -0.10

AEMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation AEMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.5x
Price/Book 47.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 43.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETHLON MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at